CORPUS CHRISTI, Texas, Dec. 8, 2005 (PRIMEZONE) -- CSMG Technologies, Inc. (OTCBB:CTUM) announced today its subsidiary Live Tissue Connect, Inc. (LTC) has begun development and testing of a new set of live biological tissue welding/bonding equipment.
The equipment is designed specifically for vessel and duct sealing procedures using an automatic mode setting from the company's patented platform welding/bonding technology. The automated unit testing on vessels and ducts is expected to begin in mid-January and be completed in mid-March 2006. Tests will include vessels ranging from 3 to 14 mm diameter in size.
Following completion of the unit, LTC will complete development and testing of new equipment specifically for intestine reconnection and repair with end-to-end and end-to-side procedure techniques using an automated mode.
Don Robbins, CEO of CSMG Technologies, said, "During demonstrations, we have shown the superior capability of the tissue welding technology for repair and reconnection of tissue and hollow organs. Our technology is smokeless, generates little heat migration in the tissue, causes no necrosis and is without the use of staples, sutures, glues or sealant. Procedures are almost bloodless and completed in less time. We have successfully completed more than 3,000 clinical trials in Ukraine that demonstrate our technology to be universal in its ability to repair soft biological tissue. These surgeries have included the bonding and reconnecting of incised or separated human soft tissues for lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecology, fallopian tube, ovary and testicles and dura-matter. Little or no scarring resulted, and the normal function of the body organ or tissue was restored."
Robbins continued, "We will now focus on specific surgical equipment for surgeons. Surgical specialists and specialty procedures require specialty equipment. Our technology for these surgeons will be designed with an automatic mode requiring little or no additional adjustments. This approach meets those specialty needs and allows LTC the opportunity to license detailed procedures to companies that specialize in each procedure market."
About CTUM's Tissue Bonding Technology
CTUM's patented tissue welding/bonding device bonds through radiofrequency fusion and reconnects living soft biological tissue (organs) without the use of foreign matter or conventional wound-closing devices such as sutures, staples, sealant or glues. The technology leaves little or no scar visible to the naked eye after a few months. Unlike other tissue coagulation methods that tend to destroy tissue by charring, searing and necrosis, the CTUM patented technology bonds and reconnects incised tissue and avoids this by using a patented low-heat delivery method aimed at restoration of the normal functions of the live organs and tissue. U.S. and Australia patents have been issued with other U.S. and foreign patents pending.
In Ukraine, more than 3,000 successful human surgeries in clinical trials have been completed on various organs using a number of types of procedures. Surgeons at four Ukraine hospitals and clinics are using the tissue bonding technology in clinical trials and are performing open and laparoscopic surgical procedures.
CTUM owns the technology and exclusive world rights to the medical device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology. The technology, owned by CTUM, was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine at Kiev, Ukraine, headed by Professor B.E. Paton.
CTUM maintains offices in Corpus Christi, Texas, Washington D.C., Atlanta, Ga., and Kiev, Ukraine.
A profile for investors may be found at http://www.hawkassociates.com/csmg/profile.htm
Additional information about CSMG can be found at http://www.ctum.com or e-mail publicrelations@ctum.com. An online investor kit containing CSMG press releases, SEC filings, current Level II price quotes, interactive Java, stock charts and other useful information for investors can be found at http://www.hawkassociates.com and http://www.americanmicrocaps.com.
Investors may contact Don Robbins or K. Bruce Jones, CSMG, at (361) 887-7546, e-mail: publicrelations@ctum.com, or Frank Hawkins or Julie Marshall, Hawk Associates, at (305) 451-1888, e-mail: info@hawkassociates.com.
Safe-Harbor Statement: Under the Private Securities Litigation Reform Act of 1995. This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.